Oxis International resumes trading of common stock on Euronext Paris on April 14, 2015

Editorial Checklist Reviewed
Oxis International, Inc.Apr 10 2015NewsGuard 100/100 Score

Oxis International, Inc. (OXIS) (OXI.PA), a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015. Upon resumption of trading, the shares will trade in a double call auction trading mode (fixing) rather than the continuous trading mode formerly applicable to Oxis shares.

Anthony Cataldo, Oxis' CEO, said "We believe our new trading modality will enhance efficient trading across our markets on the OTC Bulletin Board and Euronext." This modification has been approved by Euronext Paris.

Source:

Oxis International, Inc.

Posted in: Business / Finance

Tags: , , , ,

Comments (0)

Suggested Reading

New vaccine shows potential in preventing recurrence of triple-negative breast cancer
MRI-guided SBRT reduces side effects in prostate cancer treatment
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths
How different types of bread impact cancer risk
Air pollution linked to head and neck cancer risk
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients
Scientists discover key genetic factors behind testicular cancer
Innovative urine test could improve pancreatic cancer survival rates

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients